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Abstract
Background: Dexmedetomidine has been reported to have a renal protective effect after adult open heart surgery. The authors
hypothesized that intraoperative infusion of dexmedetomidine would attenuate the decrease in renal function after pediatric open
heart surgery.
Methods:Twenty-nine pediatric patients (1–6 years) scheduled for atrial or ventricular septal defect repair were randomly assigned
to receive either continuous infusion of normal saline (control group, n=14) or dexmedetomidine (a bolus dose of 0.5mg/kg and then
an infusion of 0.5mg/kg/h) (dexmedetomidine group, n=15) from anesthesia induction to the end of cardiopulmonary bypass. Serum
creatinine (Scr) was measured before surgery (T0), 10minutes after anesthesia induction (T1), 5minutes after cardiopulmonary
bypass weaning (T2), 2hours after T2 (T3), and after postoperative day 1 (POD1) and postoperative day 2 (POD2) and estimated
glomerular ﬁltration rates (eGFRs) were calculated. Renal biomarkers were measured at T1, T2, and T3. Acute kidney injury (AKI) was
deﬁned as an absolute increase in Scr of ≥ 0.3mg/dL or a percent increase in Scr of ≥50%.
Results: The incidence of AKI during the perioperative period was signiﬁcantly higher in the control group than in the
dexmedetomidine group (64% [9/14] vs 27% [4/15], P= .042). eGFR was signiﬁcantly lower in the control group than in the
dexmedetomidine group at T2 (72.6±15.1 vs 83.9±13.5, P= .044) and T3 (73.4±15.4 vs 86.7±15.9, P= .03).
Conclusion: Intraoperative infusion of dexmedetomidine may reduce the incidence of AKI and suppress post-bypass eGFR
decline.
Abbreviations: AKI = acute kidney injury, AKIN = acute kidney injury network, ASD = atrial septal defect, BIS = bispectral index
score, CPB = cardiopulmonary bypass, CVP = central venous pressure, eGFR = estimated glomerular ﬁltration rate, FENa =
fractional excretion of sodium, HR = heart rate, IL = interleukin, KIM-1 = and kidney injury molecule-1 (KIM-1), MAP =mean arterial
pressure, NGAL = neutrophil gelatinase-associated lipocalin, POD = postoperative day, RFI = renal failure index, Scr = serum
creatinine, SNa = serum sodium, TNF = tumor necrotic factor, UAlb = urine microalbumin, Ucr = urine creatinine, UNa = urine sodium,
UNAG = urine N-acetyl-beta-D-glucosaminidase, VSD = ventricular septal defect.
Keywords: acute kidney injury, dexmedetomidine, glomerular ﬁltration rate, pediatric heart surgery
1. Introduction delay the recovery.[1] In a large prospective cohort study on AKIAcute kidney injury (AKI) is common after pediatric congenital
heart surgery under cardiopulmonary bypass (CPB) and mayEditor: Somchai Amornyotin.
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1after aortic surgery, 30-day mortality was 32.5% among patients
with an absolute increase in serum creatinine (Scr) of ≥0.5mg/dL
within the ﬁrst 48hours postoperatively, whereas mortality was
2.1% among those with an increase in Scr 0.3mg/dL.[2]
Although clinically signiﬁcant deterioration of kidney function is
rare in children after cardiac surgery,[3] 40% and 88% of
pediatric patients experience Scr doubling and AKI as deﬁned by
the pediatric-modiﬁed RIFLE criteria (risk, injury, failure, loss of
kidney function, and end-stage kidney disease) after cardiac
surgery, respectively.[4] Furthermore, AKI is known to be an
important independent factor of intensive care unit stay after CPB
in pediatric patients.[5]
ThemechanismofAKI after openheart surgery ismultifactorial.
Heart surgery with CPB provokes systemic inﬂammatory responses,
which increases inﬂammatory cytokines, endotoxin and metabolic
products.[6] It also induces ischemic reperfusion injury, oxidative
stress, and neurohormonal activation.[6] In addition, surgical stress
per se induces sympathetic activation, which leads to hemodynamic
instability and renal vasoconstriction.[7]
Dexmedetomidine has been reported to provide renal protec-
tion by improving tubular architecture and function following
renal ischemia.[8] In a previous clinical study in adults, it was
2Jo et al. Medicine (2017) 96:28 Medicinesuggested that perioperative infusion of dexmedetomidine might
reduce the incidence and severity of AKI and intensive care unit
stay after valvular heart surgery.[9]
We hypothesized that intraoperative infusion of dexmedeto-
midine would attenuate the decrease in renal function after
pediatric open heart surgery. Accordingly, the purpose of this
prospective randomized study was to investigate the effect of
intraoperative dexmedetomidine infusion on kidney function
after congenital heart surgery with CPB in pediatrics.2. Methods
The institutional review board of Gachon University Gil Hospital
approved this study (Ref: GCIRB 2013-163). The study was
registered at ClinicalTrials.gov (NCT 01920542). Parents or
legal guardians provided written informed consent for all
participants.
Thirty pediatric patients (1–6 years), scheduled for repair of a
congenital atrial septal defect (ASD) or a ventricular septal defect
(VSD), were initially enrolled in this prospective study. Patients
with a preoperative Scr of ≥0.7mg/dL, cyanotic heart disease,
any arrhythmia, patent ductus arteriosus, coarctation of the
aorta, severe left ventricular dysfunction (preoperative ejection
fraction of <50% by transthoracic echocardiography), signs of
right heart failure, preoperative inotropic drug use, vasopressor
use, active respiratory disease, or younger than 12 months were
excluded. Patients were randomly divided into control group (n=
15) or dexmedetomidine group (n=15) using a randomized list
generated using Excel 2007 (Microsoft Ofﬁce, Redmond, WA)
without stratiﬁcation.
No patient received any premedication. Anesthesia was
induced with ketamine 1 to 2mg/kg, sufentanil 1 to 2mg/kg,
and rocuronium of 0.8mg/kg. Anesthesia was maintained with
sevoﬂurane 2 to 3 vol%, rocuronium and sufentanil. A bispectral
index score was maintained between 40 and 60 during
anesthesia. Arterial catheters were inserted in the radial and
femoral arteries. A right internal jugular venous catheter was
inserted. A senior anesthesia trainee prepared 50mL of normal
saline for the control group or 50mL of dexmedetomidine (4mg/
mL) for the dexmedetomidine group. From 10 minutes after
anesthesia induction to CBP weaning, 0.5mg/kg of dexmedeto-
midine or the same volume of normal saline was infused over 10
minutes as a bolus dose and then 0.5mg/kg/h of dexmedetomi-
dine[10] or the same volume of normal saline was administered as
a maintenance dose in the dexmedetomidine and control groups,
respectively. Anesthesiologist and pediatric intensive care
providers who were blinded to the study group performed
hemodynamic care and sampling of urine and blood in the
operating room and intensive care unit, respectively.
When starting CPB and rewarming, sufentanil of 20mg (body
weight<10kg) or 30mg (body weight ≥10kg) and midazolam of
0.2mg/kg were administered. When needed, patients received
milrinone, dopamine, or epinephrine during CPB weaning
according to their condition.
According to the acute kidney injury network (AKIN) criteria,
AKI was deﬁned as an absolute increase in Scr of ≥0.3mg/dL, a
percent increase in Scr of ≥50%, or a decrease in urine output of
<0.5mL/kg/h for >6hours.[11]
Scr was measured before surgery (T0), 10minutes after
anesthesia induction (T1), 5minutes after CPB weaning (T2),
2hours after T2 (T3), and after postoperative day 1 (POD1) and
postoperative 2 day (POD2). Estimated glomerular ﬁltration rate
(eGFR) was calculated using Counahan-Barratt’s formula[12]2(eGFR [mL/min/1.73m ]= [0.43height in cm]/Scr). Serum
sodium (SNa), urine creatinine (Ucr), urine sodium (UNa), urine
N-acetyl-beta-D-glucosaminidase (UNAG), and urine microalbu-
min (UAlb) were sampled at T1, T2, and T3, and mean arterial
pressure (MAP), heart rate (HR), and central venous pressure
(CVP) were recorded at the same time points. UNAG to Ucr ratios
(UNAG/Ucr) were calculated, and renal failure index (RFI) and
fractional excretion of sodium (FENa)
[12] were calculated using
the following equations: RFI=UNaScr/Ucr, and FENa=100
(UNaScr)/(UcrSNa).
Given an AKI incidence in children after CPB of 88%[4] and
assuming a reduction of 30% at an a-error of 0.05 and a ß-error
of 90%, at least 15 patients were needed per the group when an
expected drop out rate of 10% was included.
Statistical analysis was performed using PASW Statistics ver.
13 (SPSS Inc, Chicago, IL). Results are presented as means
(standard deviations) or medians (interquartile ranges) or
number of patients. Patient characteristics and perioperative
clinical data in the 2 study groups were compared using an
independent t test or Fisher exact test, as appropriate. Group
comparisons of hemodynamic variables and renal biomarkers at
each time point were analyzed using an independent t test.
Changes in group hemodynamic variables and renal biomarkers
over time were analyzed using repeated measures analysis of
variance. Statistical signiﬁcance was accepted for P values <.05.3. Results
Of the 30 patients initially enrolled, 1 patient in the control group
was excluded from the analysis because of a change in operative
plan during operation. Accordingly, the data of 29 patients were
analyzed (Fig. 1). Patient characteristics and intraoperative data
are summarized in Table 1. Patient characteristics, total operative
times, aortic cross clamping times, and hourly urine outputs were
similar in the 2 groups. Similarly, no signiﬁcant intergroup
differences were observed between epinephrine, dopamine, and
milrinone requirements. No diuretic was used during and after
the surgery.
Hemodynamic variables were presented in Table 2. No
intergroup differences in MAP, HR, or CVP were observed at
any time point, and changes in MAP, HR, and CVP over time
were not signiﬁcantly different between 2 groups.
The renal function variables are listed in Table 3. There was no
intergroup difference in RFI, FENa, UNAG/Ucr, or UAlb/Ucr, at any
time points. The changes in RFI, FENa, UNAG/Ucr, and UAlb/Ucr
over time were not signiﬁcantly different between 2 groups
(P= .951, .892, .892, and .672, respectively). RFI and FENa
increased signiﬁcantly at T3 versus T1 (P= .015 and .019,
respectively) in the control group. UNAG/Ucr increased signiﬁ-
cantly at T3 versus T1 (P= .042) in the dexmedetomidine group.
From analysis of only the VSD patients (n=26), perioperative
renal indices also revealed no intergroup differences at any time
points, and similar changes over time between 2 groups.
The incidence of AKI during the perioperative period was
signiﬁcantly higher in the control group than in the dexmede-
tomidine group (64% [9/14] vs 27% [4/15], P= .042). Among 9
AKI patients in the control group, one was an ASD patient and
others were VSD patients. Among 4 AKI patients in the
dexmedetomidine, all were VSD patients. However, no patient
had a Scr level of >0.7mg/dL at any blood sampling time point.
Changes in Scr and eGFR are illustrated in Figure 2. No
intergroup difference in Scr was observed at any time points, and
changes in Scr over time were not signiﬁcantly different between 2
Figure 1. Patient allocation ﬂow diagram.
Jo et al. Medicine (2017) 96:28 www.md-journal.comgroups (P= .357). Scr increased signiﬁcantly at T2 and T3 versus
T0 in both groups (all P values <.001). However, eGFR was
signiﬁcantly lower in the control group than in the dexmede-
tomidine group at T2 (72.6±15.1mL/min/1.73 m2 vs 83.9±
13.5mL/min/1.73 m2, P= .044) and T3 (73.4±15.4mL/min/
1.73 m2 vs 86.7±15.9mL/min/1.73 m2, P= .03), but changes in
eGFR over time did not differ signiﬁcantly between 2 groups
(P= .694). Compared to the value at T0, eGFR decreased
signiﬁcantly at T2, T3, and T4 (P< .001, <.001, and .009,Table 1
Patient demographic and perioperative data.
Control (n=14) DEX (n=15) P
Age, mo 32±19 31±14 0.878
Sex (M/F) 9/5 9/6 0.812
Weight, kg 11.1±3.2 11.8±2.2 0.483
Height, cm 85±14 88±9 0.499
Body surface area, m2 0.50±0.11 0.53±0.07 0.394
The type of surgery (n)
ASD/VSD 2/12 1/14 0.501
Anesthesia time, min 238±50 249±55 0.676
Operation time, min 185±46 193±45 0.725
Study drug infusion time, min 124±33 126±39 0.867
Cardiopulmonary bypass time, min 106±34 107±39 0.919
Aorta cross clamping time, min 69±27 67±34 0.911
Lowest temperature, oC 32.7±1.1 32.4±1.1 0.537
Intraoperative use of vasoactive drugs (n)
Epinephrine 1 0 0.292
Dopamine 2 5 0.231
Milinone 10 9 0.518
Urine output, mL/kg/h
During CPB 2.3±1.0 2.7±2.0 0.480
After CPB 2.6±1.8 2.3±2.0 0.678
POD1 2.9±0.9 3.0±1.2 0.860
POD2 3.8±1.2 3.0±1.3 0.127
Results are presented as mean±SD or numbers of patients. After CPB=during the 2hours after
cardiopulmonary bypass weaning, ASD= atrial septal defect, Control=patients that received
intraoperative normal saline infusion, DEX=patients that received intraoperative dexmedetomidine
infusion, during CPB= from anesthesia induction to cardiopulmonary bypass weaning, POD1=
postoperative day 1, POD2=postoperative day 2, VSD= ventricular septal defect.
3respectively) in the control group and at T2 and T3 (P values
<.001) in the dexmedetomidine group. No patient received
prolonged mechanical ventilation (over 24hours) or stayed in the
intensive care unit for >2 days. Furthermore, no patient required
renal replacement therapyor diuretics during andafter the surgery.
4. Discussion
This prospective, randomized trial shows that intraoperative
dexmedetomidine (a loading dose of 0.5mg/kg followed by
infusion at 0.5mg/kg/ h) may reduce the incidence of AKI and
suppress post-bypass eGFR decline after pediatric congenital
heart surgery under CPB. However, dexmedetomidine was not
found to improve other renal biomarkers after surgery. To the
best of our knowledge, this is the ﬁrst prospective study to report
dexmedetomidine has a renal protective effect after pediatric
open cardiac surgery.
A previous multicenter trial reported that a younger age, lower
body weight, lower body surface area, and prolonged CPB time
are risk factors of AKI after pediatric cardiac surgery.[13] In theTable 2
Hemodynamic variables and renal indices.
Variables T1 T2 T3 POD 1 POD2
MAP, mmHg
Control 65±7 60±7 82±13 86±10 82±25
DEX 64±7 63±15 72±15 83±5 78±19
HR, beats/min
Control 119±17 121±13 143±18 125±8 133±23
DEX 114±16 119±13 129±21 128±15 132±11
CVP, mmHg
Control 4.6±2.3 8.8±2.6 7.6±2.5 7.0±2.9 7.3±2.0
DEX 5.1±2.9 7.1±3.4 7.1±2.2 8.1±2.5 7.9±2.0
Results are presented as mean±SD or numbers of patients or medians (interquartile ranges). Control
(n=14)=patients that received intraoperative normal saline infusion, CVP= central venous pressure,
DEX (n=15)=patients that received intraoperative dexmedetomidine infusion, HR=heart rate,
MAP=mean arterial pressure, POD1=postoperative day 1, POD2=postoperative day 2, T1=10
minutes after anesthesia induction, T2=5minutes after cardiopulmonary bypass weaning, T3=2
hours after T2.
Table 3
Perioperative renal indices.
Group T1 T2 T3
RFI Control 0.37 (0.21–0.63) 0.77 (0.32–1.02) 0.65 (0.60–1.98) )
∗
Dexmedetomidine 0.48 (0.30–1.20) 0.78 (0.56–1.46) 1.07 (0.52–1.57)
FENa (%) Control 0.27 (0.15–0.47) 0.58 (0.24–0.74) 0.47 (0.43–1.38)
∗
Dexmedetomidine 0.35 (0.22–0.88) 0.57 (0.41–1.09) 0.73 (0.39–1.14)
UNAG/Ucr, U/g Control 20.3 (12.4–36.9) 72.9 (27.5–459.6) 233.2 (26.8–1530.2)
Dexmedetomidine 22.1 (8.8–42.7) 235.2 (102.6–474.1) 422.6 (128.6–1631.0)
∗
UAlb/Ucr, mg/g Control 18.3 (12.8–55.9) 185.4 (60.1–268.5) 34.4 (16.3–461.9)
Dexmedetomidine 9.7 (9.1–70.1) 108.8 (17.8–441.7) 97.3 (17.7–372.2)
Values are medians (interquartile ranges). Control (n=14), patients that received intraoperative normal saline infusion; Dexmedetomidine (n=15), patients that received intraoperative dexmedetomidine infusion.
FENa= fractional excretion of sodium, RFI= renal failure index, T1=10minutes after anesthesia induction, T2=5minutes after cardiopulmonary bypass weaning, T3=2hours after T2, UAlb/Ucr=UAlb to Ucr
ratio, UNAG/Ucr=UNAG to Ucr ratio.∗
P< .05, vs T1.
Figure 2. Perioperative changes in serum creatinine and estimated glomerular
ﬁltration rate in patients that received normal saline (the control group, ) or
dexmedetomidine (the dexmedetomidine group, •). Error bars represent
standard deviations. POD1=postoperative day 1, POD2=postoperative day
2, T0=before surgery, T1=10minutes after anesthesia induction, T2=5
minutes after cardiopulmonary bypass weaning, T3=2hours after T2.
∗
P< .05,
vs the control group, †P< .05 vs T0.
Jo et al. Medicine (2017) 96:28 Medicinepresent study, we only included 1- to 6-year-old patients with a
simple atrial or VSD. Our patients did not have risk factors of
AKI, and no patient suffered from clinically signiﬁcant
symptoms, signs of AKI, or needed treatment for AKI before
surgery. Nonetheless, 44.8% of the patients enrolled experienced
AKI fulﬁlling the AKIN criteria.[11] We also found renal function
declined after weaning from CPB based on eGFR, RFI, FENa,
and UNAG/Ucr ratio results, which suggests that post-bypass renal
function decline is common even in low risk patients after
pediatric cardiac surgery.
Dexmedetomidine is a highly selective a2-adreno-receptor
agonist, which inhibits sympathetic outﬂow in the central
nervous system and reduces norepinephrine release in presyn-
aptic a2-receptor.
[14] These sympatholytic activities of dexme-
detomidine might help to prevent hemodynamic variations
induced by sympathetic activation after cardiac surgery.[15]
Furthermore, inhibition of circulating epinephrine and norepi-
nephrine release by dexmedetomidine might protect renal
function and stabilize hemodynamic proﬁles. A previous animal
study revealed that a2-adrenoreceptor is widely distributed in the
renal cortex and dexmedetomidine dose-dependently inhibits
stimulation-evoked norepinephrine release and induces renal
vasodilation.[16] Although no signiﬁcant intergroup differences
were observed between hemodynamic changes, in the present
study, MAP, HR, and CVP were more stable in the dexmede-
tomidine group than in the control group after weaning from
CPB. A previous study also has reported that a low bolus dose of
dexmedetomidine (0.25 or 0.5mg) had limited hemodynamic
effects in health human volunteers.[17]
During CPB, contact between blood and extracorporeal
circuit produces systemic inﬂammatory responses, the releases
of various cytokines, and the activation of inﬂammatory cells,
which can lead to kidney dysfunction.[18,19] Furthermore, an in
vitro study demonstrated that acute inﬂammatory responses, as
determined by the release of interleukin (IL)-8, after CPB
were greater in pediatrics than in adults.[20] Other studies also
demonstrated elevated serum IL-6 and -10 in children who
develop AKI after cardiac surgery.[21] Although the mechanisms
responsible for the effect of dexmedetomidine on renal function
after CPB weaning are unclear, dexmedetomidine-induced
a2-receptor activation might suppress the production of
monocytic cytokines.[22] An earlier clinical study demonstrated
that intraoperative dexmedetomidine infusion signiﬁcantly
decreased the productions of IL-1b, tumor necrotic factor-a,
and IL-10, and reduced postoperative leukocyte counts and
C-reactive protein levels.[23] Another possible mechanism is
that dexmedetomidine suppresses systemic inﬂammation via a4cholinergic anti-inﬂammatory pathway. In a previous in-vitro
study conducted using a lipopolysaccharide-induced endotox-
emia model, it was suggested that the preemptive administration
of dexmedetomidine might inhibit inﬂammatory cytokine release
by modulating the vagus nerve and an a7nAChR-mediated
cholinergic anti-inﬂammatory pathway.[24] In this present study,
we observed that eGFRs were signiﬁcantly higher in the
dexmedetomidine group, which concurs with the results of adult
studies.[9,25] In addition, a retrospective study also reported that
the use of dexmedetomidine was associated with reduced AKI
[26] [5] Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive
Jo et al. Medicine (2017) 96:28 www.md-journal.comincidence after pediatric congenital heart surgery. Thus, it is
assumed that the perioperative use of dexmedetomidine have
protective effect on renal function after open heart surgery.
As the primary target for AKI management is the prevention,
its early detection is very important after pediatric open heart
surgery. Noninvasive biomarkers for early detection of AKI are
suggested such as UNAG, UAlb, IL-18, neutrophil gelatinase-
associated lipocalin (NGAL), and kidney injury molecule-1
(KIM-1). An earlier study has reported that UAlb/Ucr was a
reliable predictor for AKI and its optimal cutoff value was >400
mg/g in pediatric open heart surgery.[27] In this present study,
UNAG/Ucr and UAlb/Ucr were measured for detecting early AKI or
renal tubular injury and there were no intergroup differences at
any time points. Also, the number of patients with UAlb/Ucr>400
mg/g at 2hours after CPB was comparable between the control
and dexmedetomidine groups (29% [4/14] vs 20% [3/15],
P= .681) in this present study.
The present study has several limitations. First, UNAG/Ucr and
UAlb/Ucr wasmeasured as renal biomarkers to detect AKI, but the
range of these biomarkers was too wide to detect intergroup
differences. Although changes in serum and urinary biomarkers
revealed a decline in renal function in both groups, the beneﬁcial
effect of dexmedetomidine on renal function was only reﬂected
with eGFR. The change in Scr levels was also similar between the
groups because it is not the most accurate marker of kidney
injury, especially during the acute phase. The use of more
sensitive biomarkers such as serum cystatin C or NGAL would
have given better assessment of renal function in early
postoperative period,[28] but Scr remains criterion standard for
diagnosing the AKI and reliable predictor of AKI even immediate
after cardiac surgery.[29] Second, the lack of inﬂammatory
cytokines makes impossible to elucidate the mechanism underly-
ing renal protective effect of dexmedetomidine. Third, the
inclusion of different risk index category patients in this study.
Risk-adjusted Congenital Heart Surgery Score (RACHS) indi-
cates that secundum ASD is category 1 and VSD is category 2,
and Li et al[13] have reported that no patients from the RACHS-1
category 1 surgeries developed AKI. However, only 3 ASD
patients were included in this study (2 in the control and 1 in the
dexmedetomidine group) and when data of only VSD patients
were analyzed, the results were the same. Lastly, although
calculated, the sample size is too small to extrapolate to pediatric
patients with various congenital heart diseases. Larger sample
size is needed for generalized results with greater precision and
power. We added these comments in the discussion section.
In conclusion, intraoperative dexmedetomidine infusion may
reduce the incidence of AKI and the incidence of post-bypass
eGFR decline after pediatric congenital heart surgery under CPB.
However, intraoperative dexmedetomidine infusion was not
found to improve renal biomarkers, such as UNAG and UAlb, after
pediatric open heart surgery.References
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